Qiagen N.V. $QGEN Shares Sold by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA lowered its stake in shares of Qiagen N.V. (NYSE:QGEN) by 3.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 24,525,073 shares of the company’s stock after selling 776,274 shares during the period. Massachusetts Financial Services Co. MA owned approximately 11.03% of Qiagen worth $1,178,675,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in QGEN. SVB Wealth LLC purchased a new position in shares of Qiagen in the 1st quarter worth about $31,000. Farther Finance Advisors LLC increased its position in shares of Qiagen by 400.5% in the second quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock worth $51,000 after acquiring an additional 849 shares in the last quarter. Allworth Financial LP raised its stake in shares of Qiagen by 260.1% in the 2nd quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock valued at $53,000 after acquiring an additional 796 shares during the period. Cullen Frost Bankers Inc. raised its stake in shares of Qiagen by 13,144.4% in the 2nd quarter. Cullen Frost Bankers Inc. now owns 1,192 shares of the company’s stock valued at $57,000 after acquiring an additional 1,183 shares during the period. Finally, Hilltop National Bank acquired a new position in shares of Qiagen during the 2nd quarter valued at $66,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Wall Street Zen raised shares of Qiagen from a “hold” rating to a “buy” rating in a research report on Saturday, November 1st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Qiagen in a report on Thursday. Barclays set a $53.00 price target on shares of Qiagen and gave the stock an “overweight” rating in a research note on Thursday, October 2nd. UBS Group upped their price objective on shares of Qiagen from $48.00 to $50.00 and gave the company a “neutral” rating in a research report on Thursday, August 7th. Finally, Cowen reaffirmed a “hold” rating on shares of Qiagen in a research report on Thursday, August 7th. Three equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $49.69.

Qiagen Trading Down 0.7%

Shares of NYSE QGEN opened at $44.34 on Friday. Qiagen N.V. has a 12-month low of $37.63 and a 12-month high of $51.88. The company has a market cap of $9.86 billion, a price-to-earnings ratio of 26.20, a price-to-earnings-growth ratio of 2.48 and a beta of 0.64. The company has a current ratio of 1.61, a quick ratio of 1.35 and a debt-to-equity ratio of 0.25. The stock’s 50 day simple moving average is $46.19 and its 200 day simple moving average is $46.52.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.03. The company had revenue of $533.00 million for the quarter, compared to analysts’ expectations of $525.68 million. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.57 earnings per share. Qiagen has set its FY 2025 guidance at 2.380-2.380 EPS. Q4 2025 guidance at 0.600-0.600 EPS. Equities research analysts expect that Qiagen N.V. will post 2.26 EPS for the current year.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.